Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Veracyte Inc.

    NASDAQ: VCYT · Real-Time Price · USD
    26.66
    0.22 (0.83%)
    At close: Jun 16, 2025, 3:59 PM
    0.83%
    Bid 26.45
    Market Cap 2.09B
    Revenue (ttm) 463.39M
    Net Income (ttm) 33.05M
    EPS (ttm) 0.42
    PE Ratio (ttm) 63.48
    Forward PE 37.11
    Analyst Buy
    Ask 27.91
    Volume 363,569
    Avg. Volume (20D) 1,012,877
    Open 26.54
    Previous Close 26.44
    Day's Range 25.85 - 26.92
    52-Week Range 19.73 - 47.32
    Beta 2.10

    About VCYT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VCYT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    +0.46%
    Veracyte shares are trading lower. The company rep... Unlock content with Pro Subscription
    7 months ago
    +2.05%
    Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.
    news image

    2 weeks ago · businesswire.com

    Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance Prostate and Bladder Cancer Resea...

    news image

    4 weeks ago · businesswire.com

    Veracyte to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Bla...

    news image

    4 weeks ago · zacks.com

    Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?

    Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.

    news image

    1 month ago · zacks.com

    Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

    VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

    news image

    1 month ago · zacks.com

    What Makes Veracyte (VCYT) a New Buy Stock

    Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · seekingalpha.com

    Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

    Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Finan...

    news image

    1 month ago · zacks.com

    Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates

    Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.

    news image

    1 month ago · businesswire.com

    Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.

    news image

    1 month ago · businesswire.com

    Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.

    news image

    1 month ago · businesswire.com

    Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.

    Add to Watchlist